A recent study suggests a strong link between type 2 diabetes and fatty liver disease, particularly for those also struggling with obesity. This research highlights the importance of screening and early intervention to prevent severe liver damage.
Metabolic dysfunction – associated steatotic liver disease (MASLD) is a prevalent, chronic liver disease characterized by excessive fat accumulation in the liver. It is frequently linked to obesity and type 2 diabetes. Globally, MASLD affects 38% of the population, with a prevalence of 55% – 73% in those with type 2 diabetes.
The Epsonip study utilized MRIs to assess various factors in 308 type 2 diabetes patients. Results indicated that 59% of the individuals had MASLD, 7% showed suspected advanced fibrosis, and 1.9% had cirrhosis. Compared to those without MASLD, individuals with the condition exhibited a higher body mass index and a greater prevalence of obesity. A multivariable analysis confirmed obesity’s link to an eight – fold increased risk of fibrotic MASLD.
The study’s findings emphasize the need to prioritize healthcare efforts for individuals with both type 2 diabetes and obesity. Approximately 13% of this group exhibited early – stage liver scarring, a significantly higher proportion compared to the 2% in the type 2 diabetes group without obesity. The study’s lead researcher noted that screening for liver disease may be vital for managing type 2 diabetes.
Related topics:
